We represented Janssen and BTG in these patent infringement actions relating to Janssen’s prostate cancer product ZYTIGA®(abiraterone acetate). We were successful in proving inducing infringement and in resisting the defendants’ attacks based on lack of demonstrated utility, unpatentable subject-matter and sufficiency. However, the trial judge found that the claims were obvious and dismissed the actions. This case is under appeal to the Federal Court of Appeal on the issue of obviousness.